The Impact of Haematopoietic Growth Factors on Supportive Care in Clinical Oncology: With Special Attention to Potential Tumour Cell Contamination in the Stem Cell Harvest

  • C. P. Schröder
  • W. T. A. van der Graaf
  • P. H. B. Willemse
  • E. Vellenga
  • L. de Leij
  • N. H. Mulder
  • E. G. E. de Vries
Chapter
Part of the Developments in Hematology and Immunology book series (DIHI, volume 33)

Abstract

Haematopoietic growth factors (HGFs) are now for a number of years available for use in oncological patients. Drugs currently registered are: granulocyte colony stimulating factor (G-CSF) and granulocyte macrophage colony stimulating factor (GM-CSF) for neutrophil stimulation and erythropoietin for stimulation of erythropoiesis. With several other HGFs phase I, II and III studies have been performed or are ongoing. The new as yet unregistered compounds are often under investigation for their capacity to stimulate thrombopoiesis.

Keywords

Breast Cancer Bone Marrow Clin Oncol Peripheral Blood Stem Cell Autologous Bone Marrow Transplantation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rusthoven JJ, de Vries EGE, Dale DC, Piccart M, Glaspy J, Hamilton A. Consensus of the use of neutrophil-stimulating hematopoietic growth factors in clinical practice: an international viewpoint. Int J Antimicr Agents 1997;8:263–275.CrossRefGoogle Scholar
  2. 2.
    Scott DA, Schimpff SC. In: Klastersky J, Schimpff SC, Senn H-J (eds). Prevention of infection in cancer patients. Handbook of supportive care in Cancer New York: Marcel Dekker, Inc., 1995;45–62.Google Scholar
  3. 3.
    O’Reilly SE, Gelmon KA, Onetto N, et al. Phase I trial of recombinant human granulocyte-macrophage colony-stimulating factor derived from yeast in patients with breast cancer receiving cyclophosphamide, doxorubicin and fluorouracil. J Clin Oncol 1993;11:2411–2416.PubMedGoogle Scholar
  4. 4.
    Lamar RE, Greco FA, Johnson DH, Murphy PB, Hainsworth JD. High-dose brief duration, multiagent chemotherapy for metastatic breast cancer. Cancer 1994;73: 1842–1848.PubMedCrossRefGoogle Scholar
  5. 5.
    Hoagland HC. Hematologic complications of cancer chemotherapy. In: Perry MC (ed). The chemotherapy source book. Baltimore: Williams and Wilkens, 1992;498–507.Google Scholar
  6. 6.
    Klastersky J. Prevention of infection in neutropenic cancer patients. Curr Opinion Oncol 1996;8:270–277.CrossRefGoogle Scholar
  7. 7.
    Hartmann LC, Tschetter LK, Habermann TM, et al. Granulocyte colony stimulating factor in severe chemotherapy-induced afebrile neutropenla. N Engl J Med 1997; 336:1776–1780.PubMedCrossRefGoogle Scholar
  8. 8.
    Sleijfer DT, Mulder NH, de Vries-Hospers HG, et al. Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract. Eur J Cancer 1980;16:859–869.PubMedCrossRefGoogle Scholar
  9. 9.
    Warren R. Protecting neutropenic patients from bowel-derived organisms. J Hosp Infect 1991;9(suppl c):43–58.CrossRefGoogle Scholar
  10. 10.
    De Vries-Hospers HG, Sleijfer DT, Mulder NH, et al. Bacteriological aspects of selective decontamination of the digestive tract as a method of infection prevention in granulocytopenic patients. Antimicrob Agents Chemother 1981; 19:813–820.PubMedCrossRefGoogle Scholar
  11. 11.
    Maiche AG. Use of quinolones in the immunocompromised host. Eur J Clin Microbiol Infect Dis 1991;10:361–367.PubMedCrossRefGoogle Scholar
  12. 12.
    Bow EJ, Loewen R, Vaughan D. Reduced requirement for antibiotic therapy targeting Gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones. Clin Infect Dis 1995; 20:907–912.PubMedCrossRefGoogle Scholar
  13. 13.
    Klastersky J. Prevention and therapy of fungal infections in cancer patients:a review of recently published information. Support Care Cancer 1995;3:393–401.PubMedCrossRefGoogle Scholar
  14. 14.
    De Vries-Hospers HG, Mulder NH, Sleijfer DT, van Saene HKF. The effect of amphotericin B lozenges on the presence and number of Candida cells in the oropharynx of neutropenic leukemia patients. Infection 1982; 10:71–75.PubMedCrossRefGoogle Scholar
  15. 15.
    Gilbert C, Meisenberg B, Vredenburgh J, et al. Sequential prophylactic oral and empiric once-daily parental antibiotics for neutropenia and fever after high-dose chemotherapy and autologous bone marrow support. J Clin Oncol 1994; 12:1005–1011.PubMedGoogle Scholar
  16. 16.
    Maiche AG, Muhonen T. Granulocyte colony-stimulating factor (G-CSF) with or without a quinolone in the prevention of infection in cancer patients. Eur J Cancer 1993;10:1403–1405.CrossRefGoogle Scholar
  17. 17.
    Karp JE, Merz WG, Hendricksen C, et al. Oral norfloxacin for prevention of gramnegative bacteriaJ infections in patients with acute leukemia and granulocytopenia. Ann Intern Med 1987; 106:1–7.PubMedGoogle Scholar
  18. 18.
    Hartlapp JH. Antimicrobial prophylaxis in immunocompromised patients. Drugs 1987;34 (suppl l):131–133.PubMedCrossRefGoogle Scholar
  19. 19.
    DelFavero A, Menichetti F. The new fluorinated quinolones for antimicrobial prophylaxis in neutropenic patients. Eur J Cancer 1993;29A(suppl 1):S2–S6.CrossRefGoogle Scholar
  20. 20.
    Carlson JW, Fowler JM, Saltzman AK, et al. Chemoprophylaxis with oral ciprofloxacin in ovarian cancer patients receiving taxol. Gynecol Oncol 1994;55:415–420.PubMedCrossRefGoogle Scholar
  21. 21.
    Levine MN, Bramwell K, Pritchard K, et al. The Canadian experience with intensive fluorouracil, epirubicin and cyclophosphamide in patients with early stage breast cancer. Drugs 1993;45(suppl 2):51–59.PubMedCrossRefGoogle Scholar
  22. 22.
    Van der Auwera P, Gérain J. Use of the quinolones in the prophylaxis and treatment of granulocytopenic immunocompromised cancer patients. Drugs 1993;45(suppl 3):81–90.PubMedCrossRefGoogle Scholar
  23. 23.
    Edlund C, Nord CE. Supression of the oropharyngeal and gastrointestinal microflora by ciprofloxacin: microbiological and clinical consequences. Scand J Infect Dis 1989;60(suppl):98–103.Google Scholar
  24. 24.
    Vellenga E, Uyl-de Groot CA, de Wit R, et al. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia. J Clin Oncol 1996; 14:619–627.PubMedGoogle Scholar
  25. 25.
    Ross AA, Cooper BW, Lazarus HM, et al. Detection and viability of tumour cells in peripheral blood cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993:82:2605–2610.PubMedGoogle Scholar
  26. 26.
    Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumour cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumours. Blood 1994:83:636–640.PubMedGoogle Scholar
  27. 27.
    Glaves D., Huben RP, Weiss L. Haematogenous dissemination of cells from human renal adenocarcinomas. Br J Cancer 1988:57:32–35.PubMedCrossRefGoogle Scholar
  28. 28.
    Pelkey TJ, Frierson HF, Bruns DE. Molecular and immunological detection of circulating tumour cells and micrometastases from solid tumours. Clin Chem 1996:42: 1369–1381.PubMedGoogle Scholar
  29. 29.
    Redding WH, Monaghan P, Imrie SF, et al. Detection of micrometastases in patients with primary breast cancer. Lancet 1983:2:1271–1273.PubMedCrossRefGoogle Scholar
  30. 30.
    Berger U, Bettelheim R, Mansi JL, Easton D, Coombes RC, Neville AM. The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumour in breast cancer and prognosis. Am J Clin Pathol 1988:90:1–6.PubMedGoogle Scholar
  31. 31.
    Cote RJ, Rosen PP, Lesser ML, Old LJ, Osborne MP. Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. J Clin Oncol 1991:9:1749–1756.PubMedGoogle Scholar
  32. 32.
    Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul A, Bastert G. Detection of tumour cells in bone marrow of patients with primary breast cancer:a prognostic factor for distant metastasis. J Clin Oncol 1992; 10:1534–1539.PubMedGoogle Scholar
  33. 33.
    Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G. Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 1993:85:1419–1424.PubMedCrossRefGoogle Scholar
  34. 34.
    Pantel K, lzbicki JR, Angstwurm M, et al. Immunocytological detection of bone marrow métastases in operable non-small cell lung cancer. Cancer Res 1993:53: 1027–1031.PubMedGoogle Scholar
  35. 35.
    Pantel K, lzbicki JR, Passlick B, et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small cell lung cancer without overt métastases. Lancet 1996;347:649–653.PubMedCrossRefGoogle Scholar
  36. 36.
    Mansi JL, Easton D, Berger U, et al. Bone marrow metastases in primary breast cancenprognostic significance after 6 years of follow up. Eur J Cancer 1991:27: 1552–1555.PubMedCrossRefGoogle Scholar
  37. 37.
    Schlimok G, Funke I, Pantel K, et al. Micrometastatic tumour cells in bone marrow of patients with gastric cancer: methodological aspects of detection and prognostic significance. Eur J Cancer 1991;27:1461–1465.PubMedCrossRefGoogle Scholar
  38. 38.
    Lindemann F, Schlimok G, Dirschedl P, Witte J, Riethmuller G. Prognostic significance of micrometastatic tumour cells in bone marrow of colorectal patients. Lancet 1992;340:685–689.PubMedCrossRefGoogle Scholar
  39. 39.
    Negrin RS, Blume KG. The use of the polymerase chain reaction for the detection of minimal residual malignant disease. Blood 1991;78:255–258.PubMedGoogle Scholar
  40. 40.
    Gribben JG, Freedman AS, Nueberg D, et al. Immunologie purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991;325:1525–1533.PubMedCrossRefGoogle Scholar
  41. 41.
    Gribben JG, Nueberg D, Freedman AS, et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993:81:3449–3457.PubMedGoogle Scholar
  42. 42.
    Gribben JG, Nueberg D, Barber M, et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive than detection in bone marrow. Blood 1994;83: 3800–3807.PubMedGoogle Scholar
  43. 43.
    Johnson PWM, Burchill SA, Selby PJ. The molecular detection of circulating tumour cells. Br J Cancer 1995;72:268–276.PubMedCrossRefGoogle Scholar
  44. 44.
    Gerhard M, Juhl H, Kalthoff H, Shreiber HW, Wagener C, Neumaier M. Specific detection of carcinoembryonic antigen-expressing tumour cells in bone marrow aspirates by polymerase chain reaction. J Clin Oncol 1994:12:725–729.PubMedGoogle Scholar
  45. 45.
    Ghossein RA, Shcr HI, Gerald WL, Kelley WK, Curley T, Amsterdam A. Detection of circulating tumour cells in patients with localized and metastatic prostatic carcinoma: clinical implications. J Clin Oncol 1995:13:1195–1200.PubMedGoogle Scholar
  46. 46.
    Vormwald-Dogan V, Nickel P, Willemse M, Thome M, Tilgen W. Prevalence of melanoma cells in peripheral blood of patiens with malignant-melanoma stage I-IV-detection by polymerase chain reaction. J Invest Dermatol 1994:103:400–405.Google Scholar
  47. 47.
    Mattano LA, Moss TJ, Emerson SG. Sensitive detection of rare circulating neuro-blastoma cells by the reverse transcriptase-polymerase chain reaction. Cancer Res 1992:52:4701–4705.PubMedGoogle Scholar
  48. 48.
    Datta YH, Adams PT, Drobyski WR, Ethier SP, Terry VH. Sensitive detection of occult breast cancer by the reverse-transcriptase polymerase chain reaction. J Clin Oncol 1994:12:475–482.PubMedGoogle Scholar
  49. 49.
    Traweek ST, Liu J, Battifora H. Keratin gene expression in non-epithelial tissues. Detection with polymerase chain reaction. Am J Pathol 1993; 142:1111–1118.PubMedGoogle Scholar
  50. 50.
    Dwenger A, Lindemann A, Mertelsmann R. Minimal residual disease:detection. clinical relevance and treatment strategies. J Hematother 1996:5:537–548.PubMedCrossRefGoogle Scholar
  51. 51.
    Osborne MP, Wong GY, Asina S, Old LJ, Cote RJ, Rosen PP. Sensitivity of immunoeytochemical detection of breast cancer cells in human bone marrow. Cancer Res 1991;51:2706–2709.PubMedGoogle Scholar
  52. 52.
    Zippelius A, Kufer P, Honold G, et al. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cells in bone marrow. J Clin Oncol 1997;15:2701–2708.PubMedGoogle Scholar
  53. 53.
    Helfrich W, Ten Poele R, Meersma GJ, et al. A quantitative reverse transcriptase polymerase chain reaction-based assay to detect carcinoma cells in peripheral blood. Br J Cancer 1997:76:29–35.PubMedCrossRefGoogle Scholar
  54. 54.
    De Leij L, Helfrich W, Stein R, Mattes ML SCLC cluster 2 antibodies detect the pancarcinom/epithelial glycoprotein EGP-2. Int J Cancer 1994;8:60–63.CrossRefGoogle Scholar
  55. 55.
    Helfrich W, Wittop Koning P, The TH, de Leij L. Epitope mapping of SCLC cluster 2 MABs and generation of antibodies directed against new EGP-2 epitopes. Int J Cancer 1994;8:64–69.CrossRefGoogle Scholar
  56. 56.
    Luppi M, Morselli M, Bandied E, et al. Sensitive detection of circulating breast cancer dells by reverse-transcriptase polymerase chain reaction of maspin gene. Ann Oncol 1997;7:619–624.CrossRefGoogle Scholar
  57. 57.
    Ross AA, Miller GW, Moss TJ, et al. Immunocytochemical detection of tumour cells in bone marrow and peripheral blood stem cell collections from patients with ovarian cancer. Bone Marrow Transpl 1995;15:929–933.CrossRefGoogle Scholar
  58. 58.
    Passos-Coehlo, Ross AA, Kahn DJ. Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. J Clin Oncol 1996;14:2569–2575.Google Scholar
  59. 59.
    Meagher RC, Moss TJ, Cooper B, et al. Association of mobilization regimen on tumour contamination of stem cell products (PBSC) taken from patients with stage IV breast cancer. Proc Am Soc Clin Oncol 1997; 16:415.Google Scholar
  60. 60.
    Glück S, Ross AA, Layton TJ, et al. Detection of breast cancer cells in the apheresis products (AP) and their potential clinical significance. Proc Am Soc Clin Oncol 1997; 16:392.Google Scholar
  61. 61.
    Moss TJ, Cooper B, Kennedy MJ, et al. The prognostic value of immunocytochemical (ICC) analysis on bone marrow (BM) and stem cell products (PBSC) taken from patients with stage IV breast cancer undergoing autologous transplant (ABMT) therapy. Proc Am Soc Clin Oncol 1997; 16:317.Google Scholar
  62. 62.
    Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993;341:85–86.PubMedCrossRefGoogle Scholar
  63. 63.
    Deisseroth AB, Zu Z, Claxton D. Genetic marking shows that Ph + cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 1994;83:3068–3076.PubMedGoogle Scholar
  64. 64.
    Champlin R. Purging: elimination of malignant cells from autologous blood or marrow transplants. Curr Opin Oncol 1996;8:79–83.PubMedCrossRefGoogle Scholar
  65. 65.
    Kvalheim G, Wang MY, Pharo A, et al. Purging of tumour cells from leucapheresis products: experimental and clinical aspects. J Hematother 1996;5:427–436.PubMedCrossRefGoogle Scholar
  66. 66.
    Passos-Coelho J, Ross AA, Davis JM, et al. Bone marrow micrometastases in chemotherapy-responsive advanced breast canceneffect of ex vivo purging with 4-hydro-peroxy-cyclophosphamide. Cancer Res 1994;54:2366–2371.PubMedGoogle Scholar
  67. 67.
    Anderson IC, Shpall EJ, Leslie DS, et al. Elimination of malignant clonogenic breast cancer cells from human bone marrow. Cancer Res 1989;49:4659–4664.PubMedGoogle Scholar
  68. 68.
    Vredenburgh J, Shpall EJ, Ross M, et al. Immunopharmacologic bone marrow purging and high-dose chemotherapy with autologous bone marrow for patients with metastatic breast cancer. Proc Am Soc Clin Oncol 1992; 11:58.Google Scholar
  69. 69.
    Mykleburst AT, Godal A, Juell S, Pharo A, Fodstad T. Comparison of two antibody based methods for elimination of breast cancer cells from human bone marrow. Cancer Res 1994;54:209–214.Google Scholar
  70. 70.
    Verma UN, Areman E, Dickerson SA, Kotula PL, Sacher R, Mazumder A. Interleu-kin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effectors. Bone Marrow Transpl 1995;15:199–206.Google Scholar
  71. 71.
    Wing EJ, Mitchell Magee D, Whiteside TL, Kaplan S, Shadduck RK. Recombinant human granulocyte-macrophage colony-stimulating factor enhances monocyte cyto-toxicity and secretion of tumour necrosis factor alpha and interferon in cancer patients. Blood 1989;73:643–646.PubMedGoogle Scholar
  72. 72.
    Nagler A, Shurt I, Barak V, Fabian I. Granulocyte-macrophage colony-stimulating factor dependent monocyte-mediated cytotoxicity post-autologous bone marrow transplantation. Leuk Res 1996;20:637–643.PubMedCrossRefGoogle Scholar
  73. 73.
    Beyunes MC, Higuchi C, York A, et al. Immunotherapy with interleukin-2 with or without lymphokine-activated killer cells after autologous bone marrow transplantation for malignant lymphoma: a feasibility trial. Bone Marrow Transpl 1995; 16:283–288.Google Scholar
  74. 74.
    Sphall EJ, Stemmer SM, Bearman SI, Myers S, Purdy M, Jones RB. New strategies in marrow purging for breast cancer patients receiving high-dose chemotherapy with autologous bone marrow transplantation. Breast Cancer Res Treatm 1993;26:S19-S23.Google Scholar
  75. 75.
    Berendson PJ, Bensinger WI, Hill RS, et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991;77:1717–1722Google Scholar
  76. 76.
    Dunbar CE, Cottier-Fox M, O’Shaughnessy JA, et al. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995;85:3048–3057.PubMedGoogle Scholar
  77. 77.
    Mapara MY, Körner IJ, Hildebrandt M, et al. Monitoring of tumour cell purging after highly efficient immunomagnetic selection of CD34 cells from leukapheresis products in breast cancer patients: comparison of immunocytochemical tumour cell staining and reverse transcriptase-polymerase chain reaction. Blood 1997;89:337–344.PubMedGoogle Scholar
  78. 78.
    Pantel K, Felber E, Schlimok G. Detection and characterization of residual disease in breast cancer. J Hematother 1994;3:315–322.PubMedCrossRefGoogle Scholar
  79. 79.
    Riethmüller G, Schneider-Gädicke, Schlimnok G. et al. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet 1994;343:1177–1183.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1998

Authors and Affiliations

  • C. P. Schröder
    • 1
  • W. T. A. van der Graaf
    • 1
  • P. H. B. Willemse
    • 1
  • E. Vellenga
    • 2
  • L. de Leij
    • 3
  • N. H. Mulder
    • 1
  • E. G. E. de Vries
    • 1
  1. 1.Department of HaematologyUniversity Hospital GroningenThe Netherlands
  2. 2.Department of ImmunologyUniversity Hospital GroningenThe Netherlands
  3. 3.Department of Medical OncologyUniversity Hospital GroningenThe Netherlands

Personalised recommendations